How Good Were Candidate Gene Guesses in Schizophrenia Genetics?

Patrick F. Sullivan

If it disagrees with experiment it is wrong. In that simple statement is the key to science. It does not make any difference how beautiful your guess is. It does not make any difference how smart you are, who made the guess, or what his name is — if it disagrees with experiment it is wrong. That is all there is to it.

—Richard Feynman

Picking a candidate gene for an association study of schizophrenia is a guess. Paraphrasing Feynman (quantum physicist, Nobelist, and legendarilly incisive thought experimentalist), the guess may fit beautifully into the core of an elegant neurobiological process. The guess might have sprung from the mind of a dauntingly brilliant researcher of sterling repute. But, even then, and perhaps especially then, a candidate gene is merely a guess. The proof of the guess is the “experiment”; the hard-nosed statistical evidence: is the association evidence with schizophrenia extremely strong?

As a field, we have been guessing at candidate genes for schizophrenia for over 40 years. If these articles were combined into a single academic career, if considered as the output of one researcher, they have had an enviable career: 1064 papers, h-index 98, and 47.2 citations/article (PubMed IDs from SZGene (2), 1965 to 2006, citations from Web of Science September 2017). The top 10 are familiar: DRD2, COMT, neuregulin 1, dysbindin, AKT1, DRD2, and DISC1. The top six papers have been cited 564 to 2007 times. Guessing at genes for schizophrenia has been an important stratagem.

In this issue of Biological Psychiatry, Johnson et al. (3) ask an important question: how good was our guesswork? They posed a clever contrast: do lists of the top 25 or the top 86 historical candidate genes for schizophrenia (2) have, as a set, better evidence of association with schizophrenia? In effect, they ask: how good was the field at guessing?

This important question was (in my opinion) fairly, thoughtfully, and comprehensively evaluated using state-of-the-art methods and the best publicly available results for schizophrenia (4). The conclusion was clear: the field was pretty bad at guessing. In the authors’ words, “. . . we found little evidence that common SNPs within these genes are any more relevant to schizophrenia than SNPs within control sets of noncandidate genes,” and they note that ~$250 million was spent on candidate gene studies (3).

Readers may raise a few obvious questions.

Question: Are gene set methods ever informative?

Answer: This is inconsistent with the data [see (3,6) for detail].

Question: This study evaluated common variation; what about rare exonic variation in these genes?

Answer: It is implausible, given that most of the original studies explicitly evaluated common variants (6). We now know that rare exon variants are very difficult to find, and the genes identified to date were not on anyone’s guess list (SETD1A and RBM12).

Question: What about epistatic interactions? (restated: the explicit initial candidate gene guesses did not pan out, so double-down on a more exotic mechanism?).

Answer: It is implausible, not parsimonious, unlikely except under fairly weird circumstances (most interactions are detectible under additivity), and inconsistent with empirical data [Extended Data Figure 7 in (4)].

But these objections miss the point. The track record of candidate gene guessers was no different from picking genes at random. Application of the candidate gene approach is predicated on the assumption of reasonably good guessing, and we cannot convincingly reject the null hypothesis (candidate gene guessing is indistinguishable from picking genes at random).

Johnson et al. (3) add importantly to the literature on this topic, in aggregate and for specific genes, and for schizophrenia as well as other psychiatric disorders. For example, one of the most highly cited articles in psychiatry (>4300 citations) was in Science in 2003 by Caspi et al. (7), who reported a gene-environment association of HTTLPR (serotonin transporter gene promoter polymorphism) and early stress on risk for major depressive disorder (7). It seems pretty clear that this study is wrong given lack of replication in a meta-analysis (N = 38,802) (8) and in an exceptionally similar study (9).

Implications? Following on from Johnson et al. (3), if candidate gene guessing does not work, how can we make progress? The strongest and most consistent clue that we have into the etiology of schizophrenia is its marked twin/pedigree heritability. How can we move from this broad clue to specific, reproducible, and actionable hypotheses about the etiology of schizophrenia? We recently put forth an agenda (10). I suggest the following. First, historical candidate gene studies did not work, and cannot work following from elementary school math and the now extensive knowledge of the genetic “architecture” of schizophrenia (10); the caveat being there may be a few edge-case exceptions. There is little evidence to support almost all of the historical candidate genes for schizophrenia (including impact factor heavy hitters such as COMT, BDNF, DISC1, and dysbindin).

The data suggest that candidate gene guessing should be retired. This is not a new statement, as candidate gene studies...
have been controversial for decades, but the case can now be made forcibly. In the scrappy, vibrant, and iconoclastic free-for-all that should characterize scientific inquiry, researchers, reviewers, journal editors, and readers can of course do whatever they choose. This includes recommending, funding, publishing, and reading/citing poor-quality candidate gene studies that do not meet the mature and widely accepted quality standards of human complex trait genomics. Schizophrenia is truly complex, and simple approaches, models, and guesswork have consistently failed. We should use approaches that have yielded evidence—but, we now know that the required sample sizes are huge. Therefore, progress requires collaboration and open-science approaches, and psychiatry is among the leaders in medicine. If you have an idea, test it out using online resources such as Functional Mapping and Annotation of Genome-Wide Association Studies (http://fuma.ctglab.nl); freely available summary statistics (http://www.med.unc.edu/pgc/); or individual-level data obtainable by application to genomic repositories such as the European Genome-Phenome Archive (https://www.ebi.ac.uk/ega), dbGaP (https://www.ncbi.nlm.nih.gov/gap), and NIMH Genomics (https://www.nimhgenetics.org).

Last, if progress requires meta-analysis and consortia (e.g., the next Psychiatric Genomics Consortium schizophrenia article has over 60,000 cases), what is one researcher to do? First, if you have an idea, test it out (see “how do we progress?” above) and, if meritorious, figure out an effective way to collaborate with groups that can put your idea to a stronger test. Second, instead of doing candidate gene genotyping, genotype with a single nucleotide polymorphism array. Single nucleotide polymorphism array prices are historically low (~$45 per subject for 700,000 markers) to get a large amount of useful information. These can be used to identify ancestry and large copy number variants, and generate genetic risk scores that summarize the inherited liability to schizophrenia. These are surely far more useful than genotyping BDNF val/met, COMT val/met, or HTTLPR. As with every technology, and although the methods are standard, there are many ways to make a complete hash of the data, and this not for the unwise, incautious, or inexperienced.

Scientific inquiry should be self-correcting. I strongly suggest that we abandon candidate gene guesswork (as historically applied) as they have only provided false directions and wasted effort. Better approaches are of proven value. Circling back to Feynman (1): “If it disagrees with experiment it is wrong. That is all there is to it.”

Acknowledgments and Disclosures
This work was supported by Swedish Research Council (Vetenskapsrådet) Grant No. D0886501 and National Institute of Mental Health Grant Nos. U01 MH109528 and R01 MH071739.

PFS reports the following potentially competing financial interests: Lundbeck (advisory committee, grant recipient), Pfizer (Scientific Advisory Board), Element Genomics (consultation fee), and Roche (speaker reimbursement).

Article Information
From the Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, North Carolina; and the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Address correspondence to Patrick F. Sullivan, M.D., FRANZCP, Department of Genetics, CB#7264, 5097 Genomic Medicine, University of North Carolina, Chapel Hill, NC, 27599-7264; E-mail: pfsulliv@med.unc.edu. Received Sep 6, 2017; accepted Sep 7, 2017.

References